Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375778 | 0.82 | MAPK14 (0.42) | TP53 | |
| SCHEMBL4874499 | 0.80 | ALDH1A1 (0.42) | P2RX7KMT2AKDM4EALDH1A1CYP2D6 | |
| SCHEMBL2032916 | 0.77 | PTGDR2 (0.37) | P2RX7MAPTCYP3A4 | |
| SCHEMBL4877819 | 0.76 | MAPK14 (0.49) | KMT2ACYP3A4CYP2C9 | |
| SCHEMBL4924074 | 0.75 | MAPK14 (0.41) | P2RX7MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL375572 | 0.75 | MDM2 (0.40) | — | |
| SCHEMBL4874101 | 0.75 | CHRNA7 (0.42) | TP53P2RX7 | |
| SCHEMBL4877829 | 0.74 | HSD11B1 (0.37) | P2RX7KMT2AKDM4ECYP2D6HPGD | |
| SCHEMBL4877832 | 0.74 | HSD11B1 (0.37) | P2RX7KMT2AKDM4ECYP2D6HPGD | |
| SCHEMBL3097072 | 0.74 | MEN1 (0.47) | TP53P2RX7MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810972-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-7713998-B2 | Nitrogenous heterocyclic compound and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | TP53 1259/4885P2RX7 366/4885MAPT 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.